Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

A Novel Neuraminidase-Dependent Hemagglutinin Cleavage Mechanism Enables the Systemic Spread of an H7N6 Avian Influenza Virus.

Kwon HI, Kim YI, Park SJ, Kim EH, Kim S, Si YJ, Song MS, Pascua PNQ, Govorkova EA, Webster RG, Webby RJ, Choi YK.

MBio. 2019 Nov 5;10(6). pii: e02369-19. doi: 10.1128/mBio.02369-19.

2.

Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.

Pascua PNQ, Marathe BM, Vogel P, Webby RJ, Govorkova EA.

J Antimicrob Chemother. 2019 May 1;74(5):1333-1341. doi: 10.1093/jac/dky560.

PMID:
30715325
3.

Author Correction for Jones et al., "Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors".

Jones JC, Kumar G, Barman S, Najera I, White SW, Webby RJ, Govorkova EA.

MBio. 2018 Nov 13;9(6). pii: e01868-18. doi: 10.1128/mBio.01868-18. No abstract available.

4.

Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors.

Jones JC, Kumar G, Barman S, Najera I, White SW, Webby RJ, Govorkova EA.

MBio. 2018 Apr 24;9(2). pii: e00430-18. doi: 10.1128/mBio.00430-18. Erratum in: MBio. 2018 Nov 13;9(6):.

5.

An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.

Kwon JJ, Choi WS, Jeong JH, Kim EH, Lee OJ, Yoon SW, Hwang J, Webby RJ, Govorkova EA, Choi YK, Baek YH, Song MS.

J Gen Virol. 2018 Mar;99(3):292-302. doi: 10.1099/jgv.0.001029.

PMID:
29493493
6.

Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.

Tewawong N, Marathe BM, Poovorawan Y, Vongpunsawad S, Webby RJ, Govorkova EA.

PLoS One. 2018 Jan 11;13(1):e0190877. doi: 10.1371/journal.pone.0190877. eCollection 2018.

7.

Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

McKimm-Breschkin JL, Jiang S, Hui DS, Beigel JH, Govorkova EA, Lee N.

Antiviral Res. 2018 Jan;149:118-142. doi: 10.1016/j.antiviral.2017.11.013. Epub 2017 Nov 21.

PMID:
29162476
8.

A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.

Marathe BM, Mostafa HH, Vogel P, Pascua PNQ, Jones JC, Russell CJ, Webby RJ, Govorkova EA.

Antiviral Res. 2017 Dec;148:20-31. doi: 10.1016/j.antiviral.2017.10.021. Epub 2017 Oct 31.

PMID:
29100887
9.

Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.

Choi WS, Jeong JH, Kwon JJ, Ahn SJ, Lloren KKS, Kwon HI, Chae HB, Hwang J, Kim MH, Kim CJ, Webby RJ, Govorkova EA, Choi YK, Baek YH, Song MS.

J Virol. 2017 Dec 14;92(1). pii: e01580-17. doi: 10.1128/JVI.01580-17. Print 2018 Jan 1.

10.

Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.

Pascua PNQ, Mostafa HH, Marathe BM, Vogel P, Russell CJ, Webby RJ, Govorkova EA.

Sci Rep. 2017 Aug 4;7(1):7345. doi: 10.1038/s41598-017-07433-z.

11.

The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.

Jones JC, Marathe BM, Vogel P, Gasser R, Najera I, Govorkova EA.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02460-16. doi: 10.1128/AAC.02460-16. Print 2017 May.

12.

Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets.

Pascua PN, Marathe BM, Burnham AJ, Vogel P, Webby RJ, Webster RG, Govorkova EA.

PLoS One. 2016 Jul 28;11(7):e0159847. doi: 10.1371/journal.pone.0159847. eCollection 2016.

13.

A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.

Jones JC, Marathe BM, Lerner C, Kreis L, Gasser R, Pascua PN, Najera I, Govorkova EA.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5504-14. doi: 10.1128/AAC.00888-16. Print 2016 Sep.

14.

Novel Highly Pathogenic Avian A(H5N2) and A(H5N8) Influenza Viruses of Clade 2.3.4.4 from North America Have Limited Capacity for Replication and Transmission in Mammals.

Kaplan BS, Russier M, Jeevan T, Marathe B, Govorkova EA, Russell CJ, Kim-Torchetti M, Choi YK, Brown I, Saito T, Stallknecht DE, Krauss S, Webby RJ.

mSphere. 2016 Apr 6;1(2). pii: e00003-16. doi: 10.1128/mSphere.00003-16. eCollection 2016 Mar-Apr.

15.

Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.

Marathe BM, Wong SS, Vogel P, Garcia-Alcalde F, Webster RG, Webby RJ, Najera I, Govorkova EA.

Sci Rep. 2016 May 25;6:26742. doi: 10.1038/srep26742.

16.

Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses.

Bao J, Marathe B, Govorkova EA, Zheng JJ.

Angew Chem Int Ed Engl. 2016 Mar 1;55(10):3438-41. doi: 10.1002/anie.201511361. Epub 2016 Feb 2.

17.

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.

Baranovich T, Jones JC, Russier M, Vogel P, Szretter KJ, Sloan SE, Seiler P, Trevejo JM, Webby RJ, Govorkova EA.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2118-31. doi: 10.1128/AAC.02457-15. Print 2016 Apr.

18.

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.

Reddy MB, Yang KH, Rao G, Rayner CR, Nie J, Pamulapati C, Marathe BM, Forrest A, Govorkova EA.

PLoS One. 2015 Oct 13;10(10):e0138069. doi: 10.1371/journal.pone.0138069. eCollection 2015.

19.

Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.

Song MS, Marathe BM, Kumar G, Wong SS, Rubrum A, Zanin M, Choi YK, Webster RG, Govorkova EA, Webby RJ.

J Virol. 2015 Nov;89(21):10891-900. doi: 10.1128/JVI.01514-15. Epub 2015 Aug 19.

20.

Mammalian adaptation of influenza A(H7N9) virus is limited by a narrow genetic bottleneck.

Zaraket H, Baranovich T, Kaplan BS, Carter R, Song MS, Paulson JC, Rehg JE, Bahl J, Crumpton JC, Seiler J, Edmonson M, Wu G, Karlsson E, Fabrizio T, Zhu H, Guan Y, Husain M, Schultz-Cherry S, Krauss S, McBride R, Webster RG, Govorkova EA, Zhang J, Russell CJ, Webby RJ.

Nat Commun. 2015 Apr 8;6:6553. doi: 10.1038/ncomms7553.

21.

Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.

Baranovich T, Bahl J, Marathe BM, Culhane M, Stigger-Rosser E, Darnell D, Kaplan BS, Lowe JF, Webby RJ, Govorkova EA.

Antiviral Res. 2015 May;117:10-9. doi: 10.1016/j.antiviral.2015.02.004. Epub 2015 Feb 19.

22.

Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.

Burnham AJ, Armstrong J, Lowen AC, Webster RG, Govorkova EA.

J Virol. 2015 Apr;89(8):4575-87. doi: 10.1128/JVI.02473-14. Epub 2015 Feb 11.

23.

Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus.

Govorkova EA, Baranovich T, Marathe BM, Yang L, Taylor MA, Webster RG, Taylor GL, Connaris H.

Antimicrob Agents Chemother. 2015 Mar;59(3):1495-504. doi: 10.1128/AAC.04431-14. Epub 2014 Dec 22.

24.

Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses.

Duan S, Govorkova EA, Bahl J, Zaraket H, Baranovich T, Seiler P, Prevost K, Webster RG, Webby RJ.

Nat Commun. 2014 Oct 9;5:5029. doi: 10.1038/ncomms6029.

25.

Continuing challenges in influenza.

Webster RG, Govorkova EA.

Ann N Y Acad Sci. 2014 Sep;1323:115-39. doi: 10.1111/nyas.12462. Epub 2014 May 30. Review.

26.

Prevention of influenza by targeting host receptors using engineered proteins.

Connaris H, Govorkova EA, Ligertwood Y, Dutia BM, Yang L, Tauber S, Taylor MA, Alias N, Hagan R, Nash AA, Webster RG, Taylor GL.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6401-6. doi: 10.1073/pnas.1404205111. Epub 2014 Apr 14.

27.

Novel roles of focal adhesion kinase in cytoplasmic entry and replication of influenza A viruses.

Elbahesh H, Cline T, Baranovich T, Govorkova EA, Schultz-Cherry S, Russell CJ.

J Virol. 2014 Jun;88(12):6714-28. doi: 10.1128/JVI.00530-14. Epub 2014 Apr 2.

28.

Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA.

Antimicrob Agents Chemother. 2014 May;58(5):2718-30. doi: 10.1128/AAC.02628-13. Epub 2014 Feb 24.

29.

Risk assessment of H2N2 influenza viruses from the avian reservoir.

Jones JC, Baranovich T, Marathe BM, Danner AF, Seiler JP, Franks J, Govorkova EA, Krauss S, Webster RG.

J Virol. 2014 Jan;88(2):1175-88. doi: 10.1128/JVI.02526-13. Epub 2013 Nov 13.

30.

The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome.

Baranovich T, Burnham AJ, Marathe BM, Armstrong J, Guan Y, Shu Y, Peiris JM, Webby RJ, Webster RG, Govorkova EA.

J Infect Dis. 2014 May 1;209(9):1343-53. doi: 10.1093/infdis/jit554. Epub 2013 Oct 16.

31.

Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Burnham AJ, Baranovich T, Govorkova EA.

Antiviral Res. 2013 Nov;100(2):520-34. doi: 10.1016/j.antiviral.2013.08.023. Epub 2013 Sep 4. Review.

32.

Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate.

Marathe BM, Lévêque V, Klumpp K, Webster RG, Govorkova EA.

PLoS One. 2013 Aug 15;8(8):e71401. doi: 10.1371/journal.pone.0071401. eCollection 2013.

33.

Gain-of-function experiments on H7N9.

Fouchier RA, Kawaoka Y, Cardona C, Compans RW, García-Sastre A, Govorkova EA, Guan Y, Herfst S, Orenstein WA, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG.

Science. 2013 Aug 9;341(6146):612-3. doi: 10.1126/science.341.6146.612. No abstract available.

PMID:
23929965
34.

Avian flu: Gain-of-function experiments on H7N9.

Fouchier RA, Kawaoka Y, Cardona C, Compans RW, Fouchier RA, García-Sastre A, Govorkova EA, Guan Y, Herfst S, Kawaoka Y, Orenstein WA, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG.

Nature. 2013 Aug 8;500(7461):150-1. doi: 10.1038/500150a. No abstract available.

PMID:
23925229
35.

Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.

Govorkova EA, Baranovich T, Seiler P, Armstrong J, Burnham A, Guan Y, Peiris M, Webby RJ, Webster RG.

Antiviral Res. 2013 May;98(2):297-304. doi: 10.1016/j.antiviral.2013.02.013. Epub 2013 Feb 28.

36.

T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.

Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA.

J Virol. 2013 Apr;87(7):3741-51. doi: 10.1128/JVI.02346-12. Epub 2013 Jan 16.

37.

Influenza A (H15N4) virus isolation in Western Siberia, Russia.

Sivay MV, Baranovich T, Marchenko VY, Sharshov KA, Govorkova EA, Shestopalov AM, Webby RJ.

J Virol. 2013 Mar;87(6):3578-82. doi: 10.1128/JVI.02521-12. Epub 2013 Jan 2.

38.

Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses.

Govorkova EA.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:50-7. doi: 10.1111/irv.12044. Review.

39.

Virulence and transmissibility of H1N2 influenza virus in ferrets imply the continuing threat of triple-reassortant swine viruses.

Pascua PN, Song MS, Lee JH, Baek YH, Kwon HI, Park SJ, Choi EH, Lim GJ, Lee OJ, Kim SW, Kim CJ, Sung MH, Kim MH, Yoon SW, Govorkova EA, Webby RJ, Webster RG, Choi YK.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15900-5. Epub 2012 Sep 10.

40.

Fitness of neuraminidase inhibitor-resistant influenza A viruses.

Baranovich T, Webster RG, Govorkova EA.

Curr Opin Virol. 2011 Dec;1(6):574-81. doi: 10.1016/j.coviro.2011.08.006. Epub 2011 Oct 1. Review.

41.

Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir.

Stoner TD, Krauss S, Turner JC, Seiler P, Negovetich NJ, Stallknecht DE, Frase S, Govorkova EA, Webster RG.

Antiviral Res. 2012 Mar;93(3):322-9. doi: 10.1016/j.antiviral.2011.12.013. Epub 2012 Jan 10.

42.

Therapeutics against influenza.

Govorkova EA, McCullers JA.

Curr Top Microbiol Immunol. 2013;370:273-300. doi: 10.1007/82_2011_198. Review.

PMID:
22246228
43.

Continuing threat of influenza (H5N1) virus circulation in Egypt.

Kayali G, El-Shesheny R, Kutkat MA, Kandeil AM, Mostafa A, Ducatez MF, McKenzie PP, Govorkova EA, Nasraa MH, Webster RG, Webby RJ, Ali MA.

Emerg Infect Dis. 2011 Dec;17(12):2306-8. doi: 10.3201/eid1712.110683.

44.

Impaired wound healing predisposes obese mice to severe influenza virus infection.

O'Brien KB, Vogel P, Duan S, Govorkova EA, Webby RJ, McCullers JA, Schultz-Cherry S.

J Infect Dis. 2012 Jan 15;205(2):252-61. doi: 10.1093/infdis/jir729. Epub 2011 Dec 5.

45.

Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.

Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG.

Influenza Other Respir Viruses. 2011 May;5(Suppl 1):90-3. No abstract available.

PMID:
21751467
46.

Competitive transmissibility and fitness of oseltamivirsensitive and resistant pandemic influenza H1N1 viruses in ferrets.

Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, Webby RJ, Webster RG, Govorkova EA.

Influenza Other Respir Viruses. 2011 May;5(Suppl 1):79-82. No abstract available.

PMID:
21751461
47.

Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.

Duan S, Boltz DA, Li J, Oshansky CM, Marjuki H, Barman S, Webby RJ, Webster RG, Govorkova EA.

Antimicrob Agents Chemother. 2011 Oct;55(10):4718-27. doi: 10.1128/AAC.00316-11. Epub 2011 Jul 5.

48.

Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.

Govorkova EA, Marathe BM, Prevost A, Rehg JE, Webster RG.

Antiviral Res. 2011 Aug;91(2):81-8. doi: 10.1016/j.antiviral.2011.05.008. Epub 2011 May 27.

49.

The epidemiological and molecular aspects of influenza H5N1 viruses at the human-animal interface in Egypt.

Kayali G, Webby RJ, Ducatez MF, El Shesheny RA, Kandeil AM, Govorkova EA, Mostafa A, Ali MA.

PLoS One. 2011 Mar 21;6(3):e17730. doi: 10.1371/journal.pone.0017730.

50.

Supplemental Content

Loading ...
Support Center